Jazz Pharmaceuticals
Market Cap
US$9.4b
Last Updated
2021/01/23 23:06 UTC
Data Sources
Company Financials +
Executive Summary
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet and fair value.
Similar Companies
Share Price & News
How has Jazz Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: JAZZ is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: JAZZ's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
0.6%
JAZZ
1.0%
US Pharmaceuticals
2.3%
US Market
1 Year Return
15.7%
JAZZ
7.2%
US Pharmaceuticals
23.8%
US Market
Return vs Industry: JAZZ exceeded the US Pharmaceuticals industry which returned 7.3% over the past year.
Return vs Market: JAZZ underperformed the US Market which returned 23.7% over the past year.
Shareholder returns
| JAZZ | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.6% | 1.0% | 2.3% |
| 30 Day | 7.2% | 6.5% | 4.8% |
| 90 Day | 12.2% | 11.0% | 14.5% |
| 1 Year | 15.7%15.7% | 10.9%7.2% | 26.6%23.8% |
| 3 Year | 8.3%8.3% | 22.7%13.1% | 45.0%35.4% |
| 5 Year | 31.0%31.0% | 53.9%35.5% | 126.2%101.0% |
Long-Term Price Volatility Vs. Market
How volatile is Jazz Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
An Intrinsic Calculation For Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Suggests It's 42% Undervalued2 weeks ago | Simply Wall St
Have Insiders Been Buying Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares?1 month ago | Simply Wall St
If You Had Bought Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Three Years Ago, You Could Pocket A 12% Gain TodayValuation
Is Jazz Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
41.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: JAZZ ($168.65) is trading below our estimate of fair value ($286.29)
Significantly Below Fair Value: JAZZ is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: JAZZ is poor value based on its PE Ratio (52.5x) compared to the US Pharmaceuticals industry average (23x).
PE vs Market: JAZZ is poor value based on its PE Ratio (52.5x) compared to the US market (21.3x).
Price to Earnings Growth Ratio
PEG Ratio: JAZZ is poor value based on its PEG Ratio (2.5x)
Price to Book Ratio
PB vs Industry: JAZZ is good value based on its PB Ratio (2.8x) compared to the US Pharmaceuticals industry average (4.6x).
Next Steps
Future Growth
How is Jazz Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
20.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JAZZ's forecast earnings growth (20.9% per year) is above the savings rate (2%).
Earnings vs Market: JAZZ's earnings (20.9% per year) are forecast to grow slower than the US market (21.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: JAZZ's revenue (2.4% per year) is forecast to grow slower than the US market (10.6% per year).
High Growth Revenue: JAZZ's revenue (2.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JAZZ's Return on Equity is forecast to be high in 3 years time (23.4%)
Next Steps
Past Performance
How has Jazz Pharmaceuticals performed over the past 5 years?
1.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JAZZ has a large one-off loss of $411.4M impacting its September 30 2020 financial results.
Growing Profit Margin: JAZZ's current net profit margins (7.9%) are lower than last year (29.5%).
Past Earnings Growth Analysis
Earnings Trend: JAZZ's earnings have grown by 1.2% per year over the past 5 years.
Accelerating Growth: JAZZ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: JAZZ had negative earnings growth (-70.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.8%).
Return on Equity
High ROE: JAZZ's Return on Equity (5.3%) is considered low.
Next Steps
Financial Health
How is Jazz Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: JAZZ's short term assets ($2.6B) exceed its short term liabilities ($642.1M).
Long Term Liabilities: JAZZ's short term assets ($2.6B) exceed its long term liabilities ($2.3B).
Debt to Equity History and Analysis
Debt Level: JAZZ's debt to equity ratio (61.9%) is considered high.
Reducing Debt: JAZZ's debt to equity ratio has reduced from 82.3% to 61.9% over the past 5 years.
Debt Coverage: JAZZ's debt is well covered by operating cash flow (38.3%).
Interest Coverage: JAZZ's interest payments on its debt are well covered by EBIT (7.9x coverage).
Balance Sheet
Next Steps
Dividend
What is Jazz Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JAZZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JAZZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JAZZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JAZZ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JAZZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Bruce Cozadd (56 yo)
11.75yrs
Tenure
US$14,713,637
Compensation
Mr. Bruce C. Cozadd serves as Member of Board of Advisors at Cellares Corp. He co-founded Jazz Pharmaceuticals Public Limited Company in 2003 and has been Chairman and Chief Executive Officer since April 2...
CEO Compensation Analysis
Compensation vs Market: Bruce's total compensation ($USD14.71M) is above average for companies of similar size in the US market ($USD6.22M).
Compensation vs Earnings: Bruce's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.75yrs | US$14.71m | 0.36% $ 34.2m | |
| President & COO | 3yrs | US$4.71m | 0.020% $ 1.9m | |
| Senior VP & General Counsel | 1.5yrs | US$3.21m | 0.0037% $ 352.4k | |
| Executive VP of Research & Development and Chief Medical Officer | 1.67yrs | US$3.69m | 0.0040% $ 380.5k | |
| Executive VP & CFO | 0.83yr | no data | no data | |
| Vice President of Finance & Principal Accounting Officer | 1.42yrs | no data | 0.011% $ 1.0m | |
| Senior Vice President of Technical Operations | 1.25yrs | no data | 0.0080% $ 747.9k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP of Corporate Development & Chief Transformation Officer | 0.083yr | no data | no data | |
| Senior VP & Chief Human Resources Officer | 2.17yrs | no data | no data | |
| Senior Vice President of Finance | no data | US$1.24m | no data | |
| Senior Vice President of Sleep & CNS Medicine | no data | no data | no data |
1.5yrs
Average Tenure
54yo
Average Age
Experienced Management: JAZZ's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.75yrs | US$14.71m | 0.36% $ 34.2m | |
| Independent Director | 17yrs | US$535.07k | 0.037% $ 3.4m | |
| Independent Director | 9yrs | US$542.57k | 2.07% $ 194.4m | |
| Independent Director | 7.67yrs | US$557.57k | 0.017% $ 1.6m | |
| Independent Director | 7.67yrs | US$555.07k | 0.012% $ 1.1m | |
| Independent Director | 11.5yrs | US$547.57k | 0.032% $ 3.0m | |
| Independent Director | 11yrs | US$532.57k | 0.013% $ 1.2m | |
| Lead Independent Director | 6.67yrs | US$580.07k | 0.0063% $ 589.1k | |
| Independent Director | 6.42yrs | US$542.57k | 0.013% $ 1.2m | |
| Independent Director | 8.5yrs | US$542.57k | 0.014% $ 1.3m | |
| Independent Director | 7.67yrs | US$567.57k | 0.014% $ 1.3m | |
| Independent Director | 1.92yrs | US$1.23m | 0.0085% $ 802.4k |
8.1yrs
Average Tenure
59.5yo
Average Age
Experienced Board: JAZZ's board of directors are considered experienced (8.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: JAZZ insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Jazz Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Jazz Pharmaceuticals plc
- Ticker: JAZZ
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.396b
- Shares outstanding: 55.71m
- Website: https://www.jazzpharma.com
Number of Employees
Location
- Jazz Pharmaceuticals plc
- Waterloo Exchange
- Fifth Floor
- Dublin
- Co. Dublin
- 4
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| JAZZ | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2007 |
| J7Z | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2007 |
| JAZZ N | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jun 2007 |
Biography
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Th...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 23:06 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.